Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Direct Biologics Receives FDA Clearance to Initiate Phase 1b/2a Clinical Trial of ExoFlo™ in Patients with Medically Refractory Perianal Fistulizing Crohn’s Disease
Direct Biologics, a late-stage biotechnology company leveraging its regenerative medicine platform using extracellular vesicles (EVs) […]
Ultromics Granted FDA Breakthrough Device Designation for AI-Enhanced Cardiac Amyloidosis Detection
Ultromics, a leader in the field of artificial intelligence-powered diagnostics for heart failure, has been […]
Muscular Dystrophy Association Celebrates FDA Approval of Biogen’s Qalsody for Treatment of SOD1-ALS
The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) accelerated approval […]
Avidity Biosciences Granted FDA Fast Track Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy
Avidity Biosciences, a biopharmaceutical company committed to delivering a new class of RNA therapeutics called […]
Bridge Biotherapeutics Receives FDA Authorization to Proceed with the First-in-Human Study of BBT-207
Bridge Biotherapeutics, a clinical-stage biotech company based in South Korea and Cambridge that is advancing novel drugs for […]
MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease
MaaT Pharma, a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem […]
XORTX Announces Receipt of FDA Orphan Drug Designation to Treat Autosomal Dominant Kidney Disease
XORTX Therapeutics, a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive […]
Tesis Biosciences Announces a Novel Pharmacogenomics Test Enabling Precise, Personalized Response to Wide Range of Pharmaceuticals
Tesis Biosciences, the leader in targeted genetic sequencing, has announced a new predictive genomic test […]
Zucara Therapeutics Receives IND Clearance for Phase 2 Clinical Trial of ZT-01
Zucara Therapeutics, a diabetes-focused life sciences company developing the first once-daily therapeutic to prevent hypoglycemia […]
Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval
Gamida Cell, a cell therapy pioneer working to turn cells into powerful therapeutics, today announced […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more